Summary
H. Lundbeck A/S (Lundbeck), a subsidiary of The Lundbeck Foundation carries out the research, development, manufacturing and marketing of pharmaceuticals for the treatment of the central nervous system (CNS) related diseases including psychiatric and neurological disorders. Its products are used in the treatment of diseases such as Alzheimer's disease, depression, Parkinson's disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, epilepsy and Huntington's disease among others. The company has production facilities in Denmark, France, Italy and China and research centers in China and Denmark. Lundbeck’s products are sold primarily to pharmaceutical distributors, pharmacies and hospitals. It sells its products in Europe, USA and other countries. Lundbeck is headquartered in Valby, Denmark.
H. Lundbeck AS (LUN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
H. Lundbeck A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
H. Lundbeck A/S, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
H. Lundbeck A/S, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
H. Lundbeck A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
H. Lundbeck A/S, Medical Devices Deals, 2011 to YTD 2017 11
H. Lundbeck A/S, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
H. Lundbeck A/S, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Lundbeck Acquires Desmoteplase, Ischaemic Stroke Drug From Paion For US$27 Million 15
Venture Financing 16
Naurex Raises USD80 Million in Series C Venture Financing 16
Naurex Raises US$25 Million In Venture Financing 18
Naurex Raises US$38 Million In Series B Financing 19
Partnerships 21
Lundbeck Enters into Research Agreement with ImmunoBrain Checkpoint 21
H. Lundbeck Enters into Agreement with IBM Watson Health 21
Circuit Therapeutics Enters into Research Agreement with H. Lundbeck 22
Ossianix Expands and Extends Research Agreement with Lundbeck 23
Nanomerics, University College London and Lundbeck Enter Collaboration Agreement 23
Ossianix Enters Into Co-Development Agreement With Lundbeck 24
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma For Lu AF20513 25
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 26
Upsher-Smith Labs Enters Into Development Agreement With Lundbeck 27
Otsuka Pharma Enters Into Co-Promotion Agreement Lundbeck For Abilify 28
ImaginAb Enters Into Co-Development Agreement With H. Lundbeck For CNS Imaging Biologics 29
Lundbeck Plans To Enters Into Co-Development Agreement For Treatment Of Alzheimer’s Disease 30
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 31
Almirall Enters Into Co-Promotion Agreement With Lundbeck For Escitalopram 32
H. Lundbeck Enters Into Co-Development Agreement With Proximagen 33
Lundbeck Enters Into Collaboration With The University Of Massachusetts 34
Licensing Agreements 35
Lundbeck Enters into Licensing Agreement with Ovid Therapeutics for Gaboxadol 35
Lundbeck Enters Into Licensing Agreement With Otsuka Pharma For Lu AE58054 37
H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro 38
Lundbeck Enters Into Licensing Agreement With Cephalon 39
Equity Offering 40
H. Lundbeck Raises USD0.3 Million in Private Placement of Shares upon Exercise of Warrants 40
H. Lundbeck to Raise USD3.2 Million in Private Placement of Shares upon Exercise of Warrants 41
Chelsea Therapeutics Completes Public Offering Of Shares For US$23 Million 41
Chelsea Therapeutics Files Shelf Registration Statement For Public Offering Of US$100 Million 42
Chelsea Therapeutics Completes Public Offering Of Common Stock For US$24 Million 43
Chelsea Therapeutics International Completes Public Offering Of Its Common Stock For US$40.3 Million 44
Asset Transactions 46
Recordati Completes Acquisition Of Portfolio Of Products From Lundbeck For US$100 Million 46
Oak Pharma Acquires Three Hospital-Based Injectables From H. Lundbeck 48
Trygg Pharma Completes Acquisition Of Manufacturing Facility In UK From Lundbeck Pharma 49
Acquisition 50
H. Lundbeck Completes Acquisition of Chelsea Therapeutics for USD658 Million 50
Lundbeck Acquires 4.6% Stake In Biotie Therapies For US$13 Million 51
H. Lundbeck A/S - Key Competitors 53
Key Employees 54
Locations And Subsidiaries 55
Head Office 55
Other Locations & Subsidiaries 55
Recent Developments 59
Financial Announcements 59
May 10, 2017: Lundbeck: 2017 guidance raised based on strong revenue growth and improved profitability 59
Feb 08, 2017: Lundbeck continues to show solid revenue growth and strong improvement in profitability 60
Nov 02, 2016: Lundbeck raises its 2016 financial guidance based on improved sales and profitability 61
Aug 24, 2016: Lundbeck increased revenue by 5% driven by US sales growth of 33% leading to improved profitability and increased financial guidance for 2016 62
May 11, 2016: 2016 guidance raised based on solid sales performance and improved profitability 64
Feb 10, 2016: Solid sales performance in 2015 and return to profitability in 2016 65
Legal and Regulatory 66
Sep 08, 2016: The General Court of the EU upholds the European Commission's 2013 fining decision against Lundbeck 66
Product News 67
Apr 18, 2017: Lundbeck to Present Data on Movement Disorder and Epilepsy Therapies at AAN Annual Meeting 67
Product Approvals 68
Apr 22, 2016: FDA Accepts Lundbeck Resubmission of New Drug Application for Carnexiv (carbamazepine) 68
Clinical Trials 69
Mar 11, 2016: Lundbeck starts clinical phase III program with Lu AF35700 in patients with treatment resistant schizophrenia 69
Appendix 70
Methodology 70
About GlobalData 70
Contact Us 70
Disclaimer 70
List of Tables
H. Lundbeck A/S, Pharmaceuticals & Healthcare, Key Facts, 2016 1
H. Lundbeck A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
H. Lundbeck A/S, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
H. Lundbeck A/S, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
H. Lundbeck A/S, Deals By Therapy Area, 2011 to YTD 2017 9
H. Lundbeck A/S, Medical Devices Deals, 2011 to YTD 2017 11
H. Lundbeck A/S, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Lundbeck Acquires Desmoteplase, Ischaemic Stroke Drug From Paion For US$27 Million 15
Naurex Raises USD80 Million in Series C Venture Financing 16
Naurex Raises US$25 Million In Venture Financing 18
Naurex Raises US$38 Million In Series B Financing 19
Lundbeck Enters into Research Agreement with ImmunoBrain Checkpoint 21
H. Lundbeck Enters into Agreement with IBM Watson Health 21
Circuit Therapeutics Enters into Research Agreement with H. Lundbeck 22
Ossianix Expands and Extends Research Agreement with Lundbeck 23
Nanomerics, University College London and Lundbeck Enter Collaboration Agreement 23
Ossianix Enters Into Co-Development Agreement With Lundbeck 24
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma For Lu AF20513 25
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 26
Upsher-Smith Labs Enters Into Development Agreement With Lundbeck 27
Otsuka Pharma Enters Into Co-Promotion Agreement Lundbeck For Abilify 28
ImaginAb Enters Into Co-Development Agreement With H. Lundbeck For CNS Imaging Biologics 29
Lundbeck Plans To Enters Into Co-Development Agreement For Treatment Of Alzheimer’s Disease 30
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 31
Almirall Enters Into Co-Promotion Agreement With Lundbeck For Escitalopram 32
H. Lundbeck Enters Into Co-Development Agreement With Proximagen 33
Lundbeck Enters Into Collaboration With The University Of Massachusetts 34
Lundbeck Enters into Licensing Agreement with Ovid Therapeutics for Gaboxadol 35
Lundbeck Enters Into Licensing Agreement With Otsuka Pharma For Lu AE58054 37
H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro 38
Lundbeck Enters Into Licensing Agreement With Cephalon 39
H. Lundbeck Raises USD0.3 Million in Private Placement of Shares upon Exercise of Warrants 40
H. Lundbeck to Raise USD3.2 Million in Private Placement of Shares upon Exercise of Warrants 41
Chelsea Therapeutics Completes Public Offering Of Shares For US$23 Million 41
Chelsea Therapeutics Files Shelf Registration Statement For Public Offering Of US$100 Million 42
Chelsea Therapeutics Completes Public Offering Of Common Stock For US$24 Million 43
Chelsea Therapeutics International Completes Public Offering Of Its Common Stock For US$40.3 Million 44
Recordati Completes Acquisition Of Portfolio Of Products From Lundbeck For US$100 Million 46
Oak Pharma Acquires Three Hospital-Based Injectables From H. Lundbeck 48
Trygg Pharma Completes Acquisition Of Manufacturing Facility In UK From Lundbeck Pharma 49
H. Lundbeck Completes Acquisition of Chelsea Therapeutics for USD658 Million 50
Lundbeck Acquires 4.6% Stake In Biotie Therapies For US$13 Million 51
H. Lundbeck A/S, Key Competitors 53
H. Lundbeck A/S, Key Employees 54
H. Lundbeck A/S, Subsidiaries 55List of Figures
H. Lundbeck A/S, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
H. Lundbeck A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
H. Lundbeck A/S, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
H. Lundbeck A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
H. Lundbeck A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
H. Lundbeck A/S, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
H. Lundbeck A/S, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
H. Lundbeck A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
H. Lundbeck A/S, Medical Devices Deals, 2011 to YTD 2017 11
